Ambien Not Sleepwalking Through Scrutiny; Label Warnings Updated
Executive Summary
Sanofi's sleeping pill has been revised once again in an update that also limits the recommended dosing.
You may also be interested in...
Gender-Based Dosing For Insomnia Drugs Dissected In NEJM
CDER officials explain the rationale behind new labeling on zolpidem-containing immediate- and controlled-release products that halves the recommended dose for women. Labeling changes include a new precaution against next-day driving following use of Sanofi’s Ambien CR.
Rep. Kennedy to join Ambien lawsuit?
Rep. Patrick Kennedy (D-R.I.) says he will check himself into the Mayo Clinic for rehab after he ran into a security barrier in Washington, D.C. May. When Capitol Police picked up the disoriented congressman at 2:45 a.m., he claimed he was headed to the Capitol for a vote. In a statement, Kennedy maintained that he was not under the influence of alcohol at the time of the incident, but admitted to having taken Sanofi-Aventis' insomnia therapy Ambien and Wyeth's antihistamine Phenergan. A recently filed class action lawsuit alleges Sanofi failed to adequately warn patients of risk of sleep walking and eating with Ambien (1"The Pink Sheet" March 20,2006, p. 18)...
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.